Stocktoria
Lineage Cell Therapeutics, Inc. LCTX
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1992-03-05
Lineage Cell Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 92.5% | 95.0% | 67.2% | 78.9% | 88.3% | 93.9% | 95.1% | 94.0% |
| Operating margin | -251.6% | -226.1% | -276.5% | -153.2% | -1133.6% | -1448.4% | -1106.0% | -837.9% | -1125.0% | -995.6% |
| Net margin | -436.5% | -195.9% | -240.2% | -178.7% | -991.0% | -1130.8% | -333.1% | -922.0% | -577.7% | 566.8% |
| FCF margin | -133.6% | -249.0% | -326.9% | 4.4% | -550.6% | -1085.3% | -921.4% | -630.3% | -920.9% | -752.6% |
| Return on assets | -56.4% | -16.4% | -21.3% | -21.2% | -24.6% | -19.1% | -9.3% | -45.2% | -11.5% | 23.5% |
| Return on equity | -142.6% | -23.7% | -33.9% | -35.8% | -46.6% | -21.5% | -10.4% | -49.9% | -12.2% | 25.7% |
| Current ratio | 5.20 | 3.65 | 2.14 | 3.16 | 2.37 | 5.66 | 8.86 | 5.34 | 6.20 | 2.90 |
Source: SEC EDGAR filings · CIK 0000876343 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.